Fluoro-deoxyglucose positron emission tomography (PET) imaging has a diagnostic and
prognostic value in the initial staging, restaging, and surveillance of non–small-cell lung …

Positron emission tomography (PET)/computed tomographic scanning, using 18F-2-deoxy-
D-glucose, complements conventional imaging evaluation of patients with lung cancer. The …

Integrated positron emission tomography/computed tomography (PET/CT) has many
advantages over solitary PET and CT, which has led it to become an increasingly …

Accurate staging is essential to offer the patient the most effective available treatment and
the best estimate of prognosis. In non-small cell lung cancer (NSCLC), surgical resection …

In the Western world, lung cancer is the leading cause of cancer-related death. Nonsmall
cell lung cancer (NSCLC) accounts for 87% of all lung cancers [1]. Adequate diagnosis and …

We investigated the incremental management impact and prognostic value of staging with
18F-FDG PET/CT in patients with non–small cell lung cancer (NSCLC) being considered for …

This article discusses the role of PET/CT in contributing to precision medicine in lung cancer,
and provides the perspective of the Society of Nuclear Medicine and Molecular Imaging …

Lung cancer is a common disease and is a leading cause of death in many countries. The
management of lung cancer is directed by an optimal staging of the tumour. Integrated …

Over the past years, positron emission tomography (PET) with fluoro-2-deoxy-d-glucose
(FDG) has emerged as an important imaging modality. In the thorax, FDG-PET has been …

Since its introduction in 1974, positron emission tomography (PET) has gained widespread
use, especially in diagnosis and staging of lung cancer. In this respect, 18F …